Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Buckhead Capital Management LLC

Buckhead Capital Management LLC decreased its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 9.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 19,149 shares of the medical research company’s stock after selling 1,961 shares during the quarter. Buckhead Capital Management LLC’s holdings in Charles River Laboratories International were worth $3,535,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Versant Capital Management Inc grew its holdings in shares of Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after buying an additional 150 shares in the last quarter. Wolff Wiese Magana LLC acquired a new stake in Charles River Laboratories International during the third quarter worth approximately $32,000. Pinnacle Bancorp Inc. grew its stake in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares during the period. Assetmark Inc. raised its holdings in Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 173 shares during the last quarter. Finally, ORG Wealth Partners LLC acquired a new position in Charles River Laboratories International in the 4th quarter valued at $56,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CRL has been the topic of several analyst reports. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a report on Monday, November 18th. Evercore ISI raised their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research note on Thursday, November 7th. Bank of America dropped their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. TD Cowen increased their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. Finally, The Goldman Sachs Group lowered their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Three research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $200.79.

Charles River Laboratories International Stock Down 0.5 %

Shares of NYSE CRL opened at $153.20 on Friday. The stock has a fifty day moving average price of $177.23 and a 200 day moving average price of $191.71. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $275.00. The company has a market cap of $7.83 billion, a P/E ratio of 19.17, a P/E/G ratio of 6.47 and a beta of 1.37.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).